M&A / Deals Cytospire hauls in $83M for a new type of T cell engager BioPharma DiveThe British biotechnology startup is making pan-gamma delta T cell engagers it says can address the limitations of similar, existing therapies.OncologyRead full story pharminent May 5, 2026 (Last updated: May 5, 2026) BioPharma Dive The British biotechnology startup is making pan-gamma delta T cell engagers it says can address the limitations of similar, existing therapies. Oncology Read full story Post navigation Previous: Amneal Agrees to Acquire Kashiv BioSciences for Total Payment up to $1.1 BillionNext: Autoimmune disease biotech Odyssey sets terms for $225m IPO Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026